Race Oncology Ltd

  • IPO date:
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Company website

Company description

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Financial highlights

Market Capitalization$164.6995 million
P/E Ratio0
P/E Growth Ratio
Book Value0.156
Dividend Per Share0
Earnings Per Share-0.06
EBITDA-10,194.588
Profit Margin0
Operating Margin TTM-3.3422
Return on Assets TTM-0.2041
Return on Equity TTM-0.3222
Revenue TTM3,134.381

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
2011-06-30 124,812 90,423 34,389 116,462
2012-06-30 140,916 135,405 5,511 152,254
2012-12-31 85,291 77,748 7,543 84,102
2013-06-30
2013-12-31 71,140 90,100 -18,960 65,051
2014-06-30 0 0 0 95.213
2015-06-30 0.49 0 0 90.722
2016-06-30 16.98 0 0 496.201
2017-06-30 25.21 0 0 4,196.767
2018-06-30 21.66 593.137 -422.875 6,498.364
2019-06-30 17.36 532.487 -303.986 3,905.258
2020-06-30 9.32 4,111.721
2021-06-30 18.85 6,784.051
2022-06-30 53.92 11,963.7
2023-06-30 591.84 13,649.645

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
2011-06-30 10,305 380,251 273,205 5,000 5,000 99,615
2012-06-30 40,140 425,961 331,510 99,539
2012-12-31 19,131 360,834 264,983 99,539
2013-06-30 104 112 90 110
2013-12-31 25,616 289,974 191,008 99,539
2014-06-30 48 62 132 110
2015-06-30 21.29 124.47 118.78 273.2
2016-06-30 3,174.519 7,112.543 59.472 5.246 7,344.153
2017-06-30 1,696.834 6,000.861 363.572 0 8,493.301
2018-06-30 3,709.998 8,240.405 309.708 0 14,456.463
2019-06-30 988.714 5,242.025 192.119 0 15,422.621
2020-06-30 1,730.773 5,933.686 243.651 0 19,660.008
2021-06-30 9,322.436 14,245.574 523.11 0 31,495.411
2022-06-30 33,540.79 37,524.749 1,417.34 0 62,016.81
2023-06-30 21,520.368 26,637.936 1,151.795 0 61,709.155

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
2011-06-30 10,124 11,916 -3,050 2,311
2012-06-30 -10,248 6,685 31,816 2,271
2013-06-30 1,089 -27,727 -17,617 2,040
2013-12-31 6,154 3,710 4,085 2,040
2014-06-30 -92.372 -39.561 -55.912
2015-06-30 -87.269 -103.69 -26.99 21.288
2016-06-30 -317.892 -306.07 4,328.054 21.288 4,349.342
2017-06-30 -4,171.555 -2,466.143 -2,652.508 4,349.342 1,696.834
2018-06-30 -6,306.446 -3,869.392 2,013.164 1,696.834 3,709.998
2019-06-30 -3,413.546 -2,674.002 -2,721.284 3,709.998 988.714
2020-06-30 -3,580.209 -2,463.083 742.059 988.714 1,730.773
2021-06-30 -5,896.587 -4,697.578 7,591.663 1,730.773 9,322.436
2022-06-30 -11,255.893 -10,974.697 24,218.355 9,322.435 33,540.79
2023-06-30 -9,923.425 -10,651.55 -12,020.422 33,540.79 21,520.368